Framycetin

DB00452

small molecule approved

Deskripsi

A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)

Struktur Molekul 2D

Berat 614.6437
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

854 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Framycetin.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Framycetin.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Framycetin.
Cisatracurium Framycetin may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Framycetin.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Framycetin.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Framycetin.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Framycetin.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Framycetin.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Framycetin.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Framycetin.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Framycetin.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Framycetin.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Framycetin.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Framycetin.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Framycetin.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Framycetin.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Framycetin.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Framycetin.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Framycetin.
Carboplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Framycetin is combined with Carboplatin.
Foscarnet The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Framycetin.
Tenofovir disoproxil Framycetin may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Framycetin may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Framycetin may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Framycetin.
Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Zoledronic acid.
Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Alendronic acid.
Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Ibandronate.
Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Clodronic acid.
Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Risedronic acid.
Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Etidronic acid.
Incadronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Incadronic acid.
Pamidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Pamidronic acid.
Tiludronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Tiludronic acid.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Framycetin.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Framycetin.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Framycetin.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Framycetin.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Framycetin.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Framycetin.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Framycetin.
Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Framycetin.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Framycetin.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Framycetin.
Ceftazidime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Framycetin.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Framycetin.
Cefalotin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefalotin.
Nabumetone The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Nabumetone.
Ketorolac The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Ketorolac.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Tenoxicam.
Celecoxib The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Celecoxib.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefotaxime.
Tolmetin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Tolmetin.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Rofecoxib.
Piroxicam The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Piroxicam.
Methotrexate The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Methotrexate.
Cephalexin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cephalexin.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Fenoprofen.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Valaciclovir.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Valdecoxib.
Diclofenac The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Diclofenac.
Sulindac The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Sulindac.
Bacitracin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Bacitracin.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Amphotericin B.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cephaloglycin.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Flurbiprofen.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Adefovir dipivoxil.
Pentamidine The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Pentamidine.
Etodolac The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Etodolac.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Mefenamic acid.
Acyclovir The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Acyclovir.
Naproxen The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Naproxen.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Sulfasalazine.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Phenylbutazone.
Meloxicam The risk or severity of methemoglobinemia can be increased when Framycetin is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Carprofen.
Cefaclor The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefaclor.
Diflunisal The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Diflunisal.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Tacrolimus.
Ceforanide The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Ceforanide.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Salicylic acid.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Meclofenamic acid.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Acetylsalicylic acid.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Oxaprozin.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Hydrochlorothiazide.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Ketoprofen.
Balsalazide The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Balsalazide.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Ibuprofen.
Cefditoren The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefditoren.
Atazanavir The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Atazanavir.
Colistimethate The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Colistimethate.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefuroxime.
Cefapirin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefapirin.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefadroxil.
Cefprozil The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefprozil.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Ceftriaxone.
Olsalazine The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Lumiracoxib.

Target Protein

16S ribosomal RNA
30S ribosomal protein S12 rpsL
C-X-C chemokine receptor type 4 CXCR4

Referensi & Sumber

Synthesis reference: Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Kuppusamy Senthilkumar, "Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same." U.S. Patent US20120101056, issued April 26, 2012.

Contoh Produk & Brand

Produk: 35 • International brands: 7
Produk
  • Odan Proctomyxin HC
    Ointment • - • Rectal • Canada • Generic • Approved
  • Odan Proctomyxin HC Suppositories
    Suppository • - • Rectal • Canada • Generic • Approved
  • Proctol Ointment
    Ointment • - • Rectal • Canada • Approved
  • Proctol Suppositories
    Suppository • - • Rectal • Canada • Approved
  • Proctosedyl
    Ointment • - • Rectal • Canada • Approved
  • Proctosedyl
    Suppository • - • Rectal • Canada • Approved
  • Proctosedyl Ointment
    Ointment • - • Rectal • Canada • Approved
  • Proctosedyl Ointment
    Ointment • - • Rectal • Canada • Approved
Menampilkan 8 dari 35 produk.
International Brands
  • Isofra — Bouchara
  • Izofra — Bouchara
  • Leukase N — Dermapharm
  • Pola — Royal
  • Sofra-Tulle — sanofi-aventis
  • Soframycin — sanofi-aventis
  • Soframycine — Melisana

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul